By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Biotechnology. According to news reporting originating from Kurashiki, Japan, by NewsRx correspondents, research stated, "Recently, the prognosis of patients with non-small-cell lung cancer (NSCLC) has improved, thanks to the standardization of adjuvant chemotherapy and the introduction of molecular-targeted drugs, notably epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and other new anti-cancer agents. However, the survival characteristics and prognosis of patients with recurrent NSCLC after curative resection are not well understood."
Our news editors obtained a quote from the research from the Kawasaki School of Medicine, "Of the 430 consecutive patients with NSCLC who underwent complete surgical resection at our institution between January 2004 and July 2011, we included 76 patients with recurrence whose post-recurrence treatment and outcome could be confirmed. We then retrospectively evaluated the effect of prognostic factors on post-recurrence survival. There were 50 men and 26 women, and the median age at recurrence was 74.5 years. The median time from surgical resection to recurrence was 12.7 months. Thirty-eight of the 76 (50%) patients underwent multimodality treatment with surgery and preoperative and/or postoperative chemotherapy as their initial treatment. For recurrence, systemic chemotherapy was administered to 64 (84%) patients, and the disease control rate for first-line chemotherapy was 55%. The 1-and 2-year post-recurrence survival rates were 68.3 and 45.8%, respectively, and the median post-recurrence survival time was 17.7 months. Six independent prognostic factors were identified: wild-type EGFR, no adjuvant chemotherapy for the primary lung cancer, age ? 80 years at recurrence, a poor Eastern Cooperative Oncology Group performance status at recurrence, symptomatic at recurrence and no systemic chemotherapy for recurrence, which significantly decreased the post-recurrence survival. The prognosis of patients with NSCLC recurrence after surgery is currently improving. Our results suggested two new prognostic factors, adjuvant chemotherapy and EGFR mutations, neither of which have been previously reported."
According to the news editors, the research concluded: "Treatment strategies for postoperative recurrence should be established based on a more detailed subdivision of factors, such as histology and molecular markers, in the future."
For more information on this research see: Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interactive Cardiovascular and Thoracic Surgery, 2013;16(2):166-72. (Oxford University Press - www.oup.com/; Interactive Cardiovascular and Thoracic Surgery - icvts.oxfordjournals.org)
The news editors report that additional information may be obtained by contacting S. Saisho, Dept. of General Thoracic Surgery, Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan. Additional authors for this research include K. Yasuda, A. Maeda, T. Yukawa, R. Okita, Y. Hirami, K. Shimizu and M. Nakata (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Japan, Drugs, Surgery, Genetics, Oncology, Kurashiki, Treatment, Lung Neoplasms, Protein Kinases, Membrane Proteins, Cancer Gene Therapy, Phosphotransferases, Adjuvant Chemotherapy, Combined Modality Therapy, Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor, Receptor Protein Tyrosine Kinases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC